PT  - JOURNAL ARTICLE
AU  - Wang, Dapeng
AU  - Wiktor, Sabina D
AU  - Cheng, Chew W
AU  - Simmons, Katie J
AU  - Money, Ashley
AU  - Pedicini, Lucia
AU  - Carlton, Asya
AU  - Breeze, Alexander L
AU  - McKeown, Lynn
TI  - EFCAB4B (CRACR2A) genetic variants associated with COVID-19 fatality
AID  - 10.1101/2022.01.17.22269412
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.01.17.22269412
4099  - http://medrxiv.org/content/early/2022/01/18/2022.01.17.22269412.short
4100  - http://medrxiv.org/content/early/2022/01/18/2022.01.17.22269412.full
AB  - The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in more than 235 million cases worldwide and 4.8 million deaths (October 2021). Severe COVID-19 is characterised in part by vascular thrombosis and a cytokine storm due to increased plasma concentrations of factors secreted from endothelial and T-cells. Here, using patient data recorded in the UK Biobank, we demonstrate the importance of variations in Rab46 (CRACR2A) with clinical outcomes. Using logistic regression analysis, we determined that three single nucleotide polymorphisms (SNPs) in the gene EFCAB4B cause missense mutations in Rab46, which are associated with COVID-19 fatality independently of risk factors. All three SNPs cause changes in amino acid residues that are highly conserved across species, indicating their importance in protein structure and function. Two SNPs, rs17836273 (A98T) and rs36030417 (H212Q), cause amino acid substitutions in important functional domains: the EF-hand and coiled-coil domain respectively. By using molecular modelling, we suggest that the substitution of threonine at position 98 causes structural changes in the EF-hand calcium binding domain. Since Rab46 is a Rab GTPase that regulates both endothelial cell secretion and T-cell signalling, these missense variations may play a role in the molecular mechanisms underlying the thrombotic and inflammatory characteristics observed in patients with severe COVID-19 outcomes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was funded by an Medical Research Council grant awarded to Lynn Mckeown - MR/T004134/1Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The UK Biobank (application ID: 42651) https://www.ukbiobank.ac.uk/I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in this present study are available upon reasonable request to the authors